The 5 references without contexts in paper G. Lukichev B., Г. Лукичёв Б. (2006) “ВЛИЯНИЕ ИНГИБИТОРА 5-α-РЕДУКТАЗЫ ПРОСКАРА (ФИНАСТЕРИДА) НА ПРОГРЕССИРОВАНИЕ ДОБРОКАЧЕСТВЕННОЙ ГИПЕРПЛАЗИИ ПРЕДСТАТЕЛЬНОЙ ЖЕЛЕЗЫ, УМЕНЬШЕНИЕ РИСКА КРОВОПОТЕРИ И ПРОФИЛАКТИКУ ТУР-СИНДРОМА ВО ВРЕМЯ ТРАНСУРЕТРАЛЬНОЙ РЕЗЕКЦИИ // EFFECTS OF INHIBITORS OF 5-ALPHA-REDUCTASE OF PROSCAR (FINASTERIDE) ON PROGRESSING BENIGN HYPERPLASIA OF THE PROSTATE, DECREASED RISK OF BLOOD LOSS AND PROPHYLACTICS OF TUR-SYNDROME DURING ITS TRANSURETHRAL RESECTION” / spz:neicon:nefr:y:2006:i:2:p:86-90

1
Vela-Navarrete R, Gonzalez-Enguita C, Garcia-Cardoso JV et al. The impact of medical therapy on surgery for benign prostatic hyperplasia: a study comparing changes in a decade (1992-2002). BJU Int 2005; 96(7): 1045-1048
(check this in PDF content)
2
Beckman TJ, Mynderse LA. Evaluation and medical management of benign prostatic hyperplasia. Mayo Clin Proc 2005; 80(10): 1356-1362
(check this in PDF content)
3
Logan YT, Belgeri MT. Monotherapy versus combination drug therapy for the treatment of benign prostatic hyperplasia. Am J Geriatr Pharmacother 2005; 3(2): 103-104
(check this in PDF content)
4
Kaplan SA. Long-term (7 to 8-year) experience with finasteride in men with benign prostatic hyperplasia. J Urol 2003; 170(1): 341
(check this in PDF content)
5
Jimenez Cruz JF, Quecedo Gutierrez L, Del Llano Seсarнs J. Finasteride: 10 years of clinical use. Systematic review of the
(check this in PDF content)